

Erratum

Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway

**Jun Cai^{a, b}, Fang-Fang Yi^b, Zhou-Yan Bian^{c, d}, Di-Fei Shen^{c, d}, Long Yang^b,
Ling Yan^{c, d}, Qi-Zhu Tang^{c, d}, Xin-Chun Yang^b, Hongliang Li^{c, d}**

^a Cardiovascular Research Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA

^b Department of Cardiology, Beijing Chaoyang Hospital, Affiliate of Capital Medical University, Beijing, China

^c Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China

^d Cardiovascular Research Institute of Wuhan University, Wuhan, China

There is a correction concerning the correspondence details of an article published in a previous issue of the *Journal of Cellular and Molecular Medicine* [1]. The correspondence (*) symbol was attributed to both X-C Yang and H Li's names in the authors list. However, corresponding details were only presented for X-C Chang. H Li's corresponding details are as follows:

Hongliang Li, M.D., Ph.D.,
Cardiovascular Research Institute of Wuhan University,
JieFang Road 238, Wuhan 430060, China.
Tel./Fax: (86)-27-88083385
E-mail: hongliang.li@ymail.com

We apologise for this error.

- [1] **Cai J, Yi F-F, Bian Z-Y, et al.** Crocetin protects against cardiac hypertrophy by blocking MEK-ERK1/2 signalling pathway. *J Cell Mol Med.* 2009; 13: 909–25.